Thomas Cory Barta

US Patent:

6476027, Nov 5, 2002

Filed:

Dec 6, 1999

Appl. No.:

09/254531

Inventors:

Clara I. Villamil - Glenview IL
John N. Freskos - Clayton MO
Brent V. Mischke - Defiance MO
Patrick B. Mullins - St. Louis MO
Robert M. Heintz - Ballwin MO
Daniel P. Getman - Chesterfield MO
Joseph J. McDonald - Ballwin MO
Gary A. DeCrescenzo - St. Charles MO
Thomas E. Barta - Evanston IL
Daniel P. Becker - Glenview IL

Assignee:

Monsanto Company - St. Louis MO

International Classification:

A61K 3116

US Classification:

5142378, 514330, 514331, 514357, 514428, 514486, 514575, 544159, 546225, 546226, 546233, 546340, 548568, 560 13, 562621, 562623

Abstract:

An N-hydroxy sulfonyl butanamide compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated N-hydroxy sulfonyl butanamide compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

US Patent:

7358370, Apr 15, 2008

Filed:

Feb 27, 2006

Appl. No.:

11/363449

Inventors:

Kenneth He Huang - Northbrook IL, US
Jeron Eaves - Durham NC, US
Gunnar J. Hanson - Dallas TX, US
James Veal - Apex NC, US
Thomas Barta - Carrboro NC, US
Lifeng Geng - Cary NC, US
Lindsay Hinkley - Cary NC, US

Assignee:

Serenex, Inc. - Durham NC

International Classification:

C07D 231/54
A01N 43/56

US Classification:

5483601, 514403

Abstract:

Disclosed are compounds and pharmaceutically acceptable salts of Formula I.

US Patent:

7928135, Apr 19, 2011

Filed:

Oct 19, 2010

Appl. No.:

12/907571

Inventors:

Kenneth He Huang - Northbrook IL, US
Jeron Eaves - Durham NC, US
Gunnar Hanson - Dallas TX, US
James Veal - Apex NC, US
Thomas Barta - Carrboro NC, US
Lifeng Geng - Cary NC, US
Lindsay Hinkley - Cary NC, US

Assignee:

Serenex, Inc. - Durham NC

International Classification:

C07D 231/54
A01N 43/56

US Classification:

514403, 5483601

Abstract:

Disclosed are compounds and pharmaceutically acceptable salts of Formula I.

US Patent:

8309548, Nov 13, 2012

Filed:

Apr 7, 2011

Appl. No.:

13/081637

Inventors:

Kenneth He Huang - Northbrook IL, US
Jeron Eaves - Durham NC, US
Gunnar Hanson - Dallas TX, US
James Veal - Apex NC, US
Thomas Barta - Carrboro NC, US
Lifeng Geng - Cary NC, US
Lindsay Hinkley - Cary NC, US

Assignee:

Serenex, Inc. - Indianapolis IN

International Classification:

A61K 31/5377
A61K 31/454
A61K 31/415
A61K 31/405
C07D 413/12
C07D 401/12
C07D 403/12
C07D 209/04

US Classification:

5142352, 514323, 514403, 514415, 544144, 546201, 5483611, 548469

Abstract:

Disclosed are compounds and pharmaceutically acceptable salts of Formula I.

US Patent:

20040209914, Oct 21, 2004

Filed:

Dec 8, 2003

Appl. No.:

10/730403

Inventors:

Thomas Barta - Wilmette IL, US
Daniel Becker - Glenview IL, US
Louis Bedell - Prospect Heights IL, US
Terri Boehm - Ballwin MO, US
Jeffery Carroll - St. Louis MO, US
Gary DeCrescenzo - St. Charles MO, US
Yvette Fobian - Wildwood MO, US
John Freskos - Clayton MO, US
Daniel Getman - Chesterfield MO, US
Susan Hockerman - Kirkwood MO, US
Carol Howard - Fenton MO, US
Darren Kassab - O'Fallon MO, US
Stephen Kolodziej - Ballwin MO, US
Madeleine Li - Vernon Hills IL, US
Joseph McDonald - Wildwood MO, US
Deborah Mischke - Defiance MO, US
Joseph Rico - O'Fallon MO, US
Nathan Stehle - Grafton WI, US
Michael Tollefson - Dardenne Prairie MO, US
William Vernier - St. Louis MO, US
Clara Villamil - Glenview IL, US

International Classification:

A61K031/4545
A61K031/453
C 07D 4 1/02
C 07D 4 5/02

US Classification:

514/316000, 514/326000, 546/188000, 546/207000, 546/229000

Abstract:

This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.

US Patent:

20040235818, Nov 25, 2004

Filed:

Dec 29, 2003

Appl. No.:

10/747796

Inventors:

Thomas Barta - Wilmette IL, US
Daniel Becker - Glenview IL, US
Louis Bedell - Prospect Heights IL, US
Terri Boehm - Ballwin MO, US
Jeffery Carroll - St. Louis MO, US
Gary DeCrescenzo - St. Charles MO, US
Yvette Fobian - Wildwood MO, US
John Freskos - Clayton MO, US
Daniel Getman - Chesterfield MO, US
Susan Hockerman - Kirkwood MO, US
Carol Howard - Fenton MO, US
Stephen Kolodziej - Ballwin MO, US
Madeleine Li - Plainsboro NJ, US
Joseph McDonald - Wildwood MO, US
Deborah Mischke - Defiance MO, US
Joseph Rico - O'Fallon MO, US
Nathan Stehle - Grafton WI, US
Michael Tollefson - Dardenne Prairie MO, US
William Vernier - St. Louis MO, US
Clara Villamil - Glenview IL, US

International Classification:

A61K031/553
A61K031/335

US Classification:

514/211010, 514/450000

Abstract:

A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,

US Patent:

20050075374, Apr 7, 2005

Filed:

Jun 14, 2004

Appl. No.:

10/867391

Inventors:

Louis Bedell - Prospect Heights IL, US
Joseph McDonald - Wildwood MO, US
Thomas Barta - Chapel Hill NC, US
Daniel Becker - Glenview IL, US
Shashidhar Rao - Plainsboro NJ, US
John Freskos - Clayton MO, US
Brent Mischke - Defiance MO, US
Daniel Getman - Chesterfield MO, US
Gary DeCrescenzo - St. Charles MO, US
Clara Villamil - Glenview IL, US

International Classification:

C07D211/84
A61K031/44
A61K031/4015

US Classification:

514345000, 514424000, 546294000, 548530000

Abstract:

A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.